Join Our News Letter


Thank you

×
SSR Conference 
 
15 - 18 FEB 2023
Fairmont Riyadh Hotel
 
 

About the Conference

After the immense success of its previous editions and under the patronage of H.E. the Minister of Health Eng. Fahad bin Abdurrahman Al-Jalajel, the Saudi Society for Rheumatology is glad to announce the launch of the 9th Annual Conference of The Saudi Society of Rheumatology (SSRCON 2023) which will be held from February 15th to 18th 2023 at the Fairmont Riyadh Hotel.
Learn from invited speakers with large projection both from the clinical and research point of view to cover all the discussion tables that are part of the program and expand your knowledge whilst experiencing three days of cutting-edge research, unrivalled networking, posters, symposia, awards and exhibitions. 

The theme of our conference is «Addressing Revolution and challenges in Rheumatology» as we continue to celebrate the research of different rheumatology specialties and we expect this programme to be filled with information that is most relevant to our speciality at present and in the future.The conference will also tackle a wide array of main topics within the Rheumatology field namely Rheumatoid Arthritis, Systemic lupus erythematosus, Spondyloarthritis, Vasculitis, Crystal induced arthritis, Scleroderma and Antiphospholipid syndrome.

This conference is an opportunity to catch up on new developments in this complex area of medicine as we explore the latest advances in the treatment and management of rheumatic diseases. Leading experts will also present clinically relevant information that you will find immediately useful in the care of your patients.

Conference Objectives

The progression and development of the scientific thinking in Rheumatology.
Encouraging and enhancing exchange of scientific thinking in its fields amongst different in-stitutions and disciplines in the Kingdom and abroad.
Cooperating with similar scientific associations in the Kingdom and abroad.
Promoting our physicians to make the early diagnosis and management of Rheumatic and musculoskeletal diseases in the Kingdom and abroad to prevent irreversible complications.
Giving the opportunity for the members of SSR to contribute to the scientific development of its fields.
Offering consultation and performing the appropriate studies to improve the level of performance in the fields of the SSR in different institutions/disciplines.
Promoting and contributing to public health education on its fields.
Supporting our Rheumatology fellowship program at different levels

Conference Topics

01
RHEUMATOID ARTHRITIS:
  • Management Issues in Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
  • JAK inhibitors vs. Biological DMARDs, Is old still gold? (Debate)
  • Biomarkers to personalize the treatment of Rheumatoid Arthritis
  • Monotherapy vs Combination therapy in Rheumatoid 
  • Arthritis: Where are we today?
02
SYSTEMIC LUPUS ERYTHEMATOSUS:
  • T2T in SLE
  • One year in review: systemic lupus erythematosus
  • Treatment of lupus nephritis between
  • Rheumatologist and nephrologist (Debate)
  • CNS lupus
03
MISCELLANEOUS
  • Can we reverse osteoarthritis (OA)?
  • Musculoskeletal and rheumatic diseases Induced by immune checkpoint inhibitors
  • Rule of Anti-CD19 CAR T cell therapy in rheumatology diseases
  • Steroid induces osteoporosis, screen, management and follows up
  • Screening of Inflammatory bowel disease and spondyloarthritis for referring patients between rheumatology and gastroenterology
04
SPONDYLOARTHRITIS:
  • SPA: updated recommendations 2022
  • Early & Long-Term Remission of axial Spondyloarthritis
  • How do we define remission and use composite indices in Psoriatic Arthritis
  • Emerging treatment strategies in PsA & achieving Remission 
05
VASCULITIS:
  • ANCA vasculitis: current approach to treatment and guidelines
  • Vasculitis mimickers add difficulty to diagnoses
  • Primary CNS Vasculitis
06
CRYSTAL INDUCED ARTHRITIS:
  • Advancement in treating patients with uncontrolled gout
07
ANTIPHOSPHOLIPID SYNDROME:
  • Challenges in APS; seroconversion, seronegative and refractory cases (include CAPS Diagnosis and treatment)
08
SCLERODERMA:
  • Pearls in the treatment of Scleroderma (include Stem cell transplantation)
09
PEDIATRIC RHEUMATOLOGY
 
10
YOUNG INVESTIGATORS FORUM:
  • Pre-conference activities on February 15th 2023



 
Platinum Sponsors
JanssenGSKAbbvie
Gold Sponsors
AstrazenecaPFIZER PFIZER PFIZERBoehringer IngelheimSandoz
Silver Sponsors
SCHS  HIKMA HIKMA ORGANON
In Collaboration with
SCHSSCHSRheumatism Association
Executed by
EXICON


SCHS

 
Conference licence number: 23/1472